Charles Schwab Investment Management Inc. Grows Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Charles Schwab Investment Management Inc. raised its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,812,502 shares of the company’s stock after purchasing an additional 45,090 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.39% of Roivant Sciences worth $33,272,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Gladius Capital Management LP purchased a new position in shares of Roivant Sciences during the 3rd quarter valued at $35,000. US Bancorp DE raised its holdings in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares during the period. GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares in the last quarter. Quarry LP boosted its stake in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00. Following the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,551,654.85. The trade was a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,388,170 shares of company stock valued at $27,612,299 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ROIV. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Roivant Sciences presently has a consensus rating of “Buy” and a consensus target price of $18.08.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $10.66 on Monday. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06. The business has a 50 day simple moving average of $10.81 and a two-hundred day simple moving average of $11.50. The stock has a market capitalization of $7.61 billion, a PE ratio of -71.06 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.